Small-molecule LIFR inhibitors attenuate renal tubulointerstitial fibrosis
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2026-11 · 1872 (8) · 168345
DOI: 10.1016/j.bbadis.2026.168345 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2026-11. Verfasst von Jia Xin Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Guangdong Provincial Key Laboratory of Renal Fa…. Hauptthemen laut MEDLINE: Kidney Tubules, Leukemia Inhibitory Factor Receptor alpha Subunit, Renal Insufficiency, Chronic. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Beijing Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Renal tubulointerstitial fibrosis (TIF), the final common pathway of chronic kidney disease (CKD), is driven by pathological crosstalk between fibroblasts and tubular epithelial cells (TECs). Leukemia inhibitory factor (LIF) contributes to this cellular interaction by binding to LIF receptor (LIFR) and activating downstream ERK and STAT3 pathways. While novel LIFR small-molecule inhibitors EC330 and EC359 have shown therapeutic efficacy in cancer, their potential in treating kidney diseases remains unexplored. Here, we showed that LIF and LIFR were expressed at low levels in healthy adult kidneys but markedly upregulated in fibrotic kidneys, particularly in fibroblasts and TECs. Mechanistically, transforming growth factor-β1 (TGF-β1) drove LIF and LIFR expression in both cell types via a SMAD3-dependent pathway. Both EC330 and EC359 dose-dependently suppressed fibroblast activation and TEC pro-fibrotic responses induced by LIF or TGF-β1, with EC330 exhibiting a superior safety profile. In vivo, EC330 attenuated ERK and STAT3 phosphorylation in fibroblasts and TECs, significantly mitigating both developing TIF in the unilateral ischemia-reperfusion injury model and established TIF in the aristolochic acid model. Collectively, our findings demonstrate that LIFR inhibition is a viable anti-fibrotic strategy and identify EC330 as a promising drug candidate for treating CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Organ Failure Research, National Clinical Research Center for Kidney Disease, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangdong Provincial Institute of Nephrology, Division…
Förderung
- Beijing Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Zhou, J. X., Long, T. T., Liu, Y. Q., Ma, J. Y., Ma, Y. Y., Chen, Q. Z., Sun, P. X., Zhang, R., Hu, Z., Zhou, M. M., Zhu, F. X., & Nie, J. (2026). Small-molecule LIFR inhibitors attenuate renal tubulointerstitial fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1872(8), 168345. https://doi.org/10.1016/j.bbadis.2026.168345
Vancouver
Zhou JX, Long TT, Liu YQ, Ma JY, Ma YY, Chen QZ, et al. Small-molecule LIFR inhibitors attenuate renal tubulointerstitial fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2026;1872(8):168345. doi:10.1016/j.bbadis.2026.168345
BibTeX
@article{Zhou2026,
author = {Zhou, Jia Xin and Long, Tan Tan and Liu, Yi Qiao and Ma, Jing Yi and Ma, Yuan Yuan and Chen, Qing Zhou and Sun, Peng Xiao and Zhang, Rui and Hu, Zheng and Zhou, Miao Miao and Zhu, Feng Xin and Nie, Jing},
title = {Small-molecule LIFR inhibitors attenuate renal tubulointerstitial fibrosis},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
year = {2026},
volume = {1872},
number = {8},
pages = {168345},
doi = {10.1016/j.bbadis.2026.168345}
}
EUVIMED